A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study. Brachytherapy boost (BTB ...

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by conventional imaging. Among patients with high-risk nonmetastatic ...

In the phase 2 EXTEND trial, investigators randomly assigned patients with oligometastatic prostate cancer to ADT or MDT + ADT, with further stratification by intermittent vs continuous ADT that was ...

This systematic review and meta-analysis of 41 studies included 4305 patients with various cancers who underwent whole-body fluorodeoxyglucose (FDG) PET/CT for the detection of distant metastatic ...

SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a radiotherapy-based strategy compared with a radical prostatectomy ...

New findings could have implications for the use of salvage therapies. Metastasis-directed therapy (MDT) may benefit men with prostate cancer who have metastases detected on PSMA PET scans following ...

The optimal strategy for treating newly diagnosed high-risk prostate cancer remains unclear. More specifically, do these patients benefit more from radical prostatectomy or a radiotherapy-based ...

Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin–Refractory Transitional-Cell Carcinoma of the Bladder PURPOSE: To assess whether failure to maintain local control (LC) of ...